Chinese pharmaceutical companies are starting to enter the domestic pharmaceutical and biotechnology market in earnest.

This was the main observation made by the Korean industry at ‘BIO Korea 2024,’ cohosted by the Ministry of Health and Welfare and the Korea Health Industry Development Institute.

The activities of major Chinese pharmaceutical and biotech companies at this year's BIO Korea attracted industry-wide attention.

Among the companies, WuXi Biologics, a Chinese company that has grown into a global antibody contract development and manufacturing organization (CDMO), received the most attention. It set up a booth at the front of the venue and actively communicated